Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.

Thomas GrelletyCeline CallensElodie RichardAdrien BriauxValérie VélascoMarina PulidoAnthony GonçalvesPierre GestraudGaetan MacGroganHervé BonnefoiBruno Cardinaud

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

This study suggests that apocrine features can be helpful in the identification of abiraterone acetate-responders. We identified Chk1 as a putative drug target in AR-positive TNBCs.

Keyphrases

dna damage response
emergency department
oxidative stress
bioinformatics analysis
drug induced